CSPG4

Chondroitin sulfate proteoglycan 4 (CSPG4), also known as melanoma-associated chondroitin sulfate proteoglycan (MCSP), neuron-glial antigen 2 (NG2), HMW-MAA, MEL-CSPG or MSK16G, is a chondroitin sulfate proteoglycan and encoded by the CSPG4 gene. CSPG4 is essential to the growth of melanoma tumor through its modulation of integrin function and enhanced growth factor receptor regulated pathways. Therefore, CSPG4 is related to melanoma.


CAR Vector Products Product list:

Catalog Targeting
Cell Type
Generation Antibody
Clone
Vector
Length
Vector
Type
Vector Design Antibody
Host
Data
sheet
Price
CAR-LC134 T cell Second 763.74 ~8kb Retroviral scFv-CD28-CD3ζ Mouse Inquiry
CAR-MZ116 T cell Second TP41.2 ~8kb Retroviral scFv-CD28-CD3ζ Mouse Inquiry
CAR-MZ117 T cell Second 149.53 ~8kb Retroviral scFv-CD28-CD3ζ Mouse Inquiry
CAR-MZ118 T cell Second G71.1 ~8kb Retroviral scFv-CD28-CD3ζ Mouse Inquiry
CAR-MZ198 T cell First 763.74 ~8kb Retroviral scFv-CD3ζ Mouse Inquiry
CAR-MZ200 T cell Second 763.74 ~8kb Retroviral scFv-41BB-CD3ζ Mouse Inquiry

CAR Viral Particles Product list:

Catalog Antibody
Clone
Packaging
System
Generation Gene
Construct
Promotor Packaging
Cell
Titer Data
sheet
Price
VP-CAR-LC618 763.74 Lentivirus Second scFv (763.74)-CD28-CD3ζ CMV 293T > 10⁷ IFU/ml Inquiry
VP-CAR-LC815 TP41.2 Lentivirus Second scFv (TP41.2)-CD28-CD3ζ CMV 293T > 10⁷ IFU/ml Inquiry
VP-CAR-LC816 149.53 Lentivirus Second scFv (149.53)-CD28-CD3ζ CMV 293T > 10⁷ IFU/ml Inquiry
VP-CAR-LC817 G71.1 Lentivirus Second scFv (G71.1)-CD28-CD3ζ CMV 293T > 10⁷ IFU/ml Inquiry
VP-CAR-LC888 763.74 Lentivirus First scFv (763.74)-CD3ζ CMV 293T > 10⁷ IFU/ml Inquiry
VP-CAR-LC889 763.74 Lentivirus Second scFv (763.74)-41BB-CD3ζ CMV 293T > 10⁷ IFU/ml Inquiry
CONTACT US

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-871-5806
Fax: 1-631-207-8356
Email:

Europe
Ringstrasse 4, 64401 Gross-Bieberau, Germany
Tel: 44-207-048-3343

Distributors

To view the contact information for a specific location, select the desired country:

Australia
australia

FOLLOW US ON